Human Growth Hormone Drugs

Human Growth Hormone Drugs

Global Human Growth Hormone Drugs Market to Reach US$5.2 Billion by 2030

The global market for Human Growth Hormone Drugs estimated at US$3.9 Billion in the year 2023, is expected to reach US$5.2 Billion by 2030, growing at a CAGR of 4.2% over the analysis period 2023-2030. Subcutaneous Administration, one of the segments analyzed in the report, is expected to record a 4.7% CAGR and reach US$3.4 Billion by the end of the analysis period. Growth in the Intramuscular Administration segment is estimated at 3.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.4 Billion While China is Forecast to Grow at 5.8% CAGR

The Human Growth Hormone Drugs market in the U.S. is estimated at US$1.4 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$358.1 Million by the year 2030 trailing a CAGR of 5.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.8% and 3.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.5% CAGR.

Global Human Growth Hormone Drugs Market - Key Trends and Drivers Summarized

Human Growth Hormone (HGH) drugs consist of synthetic forms of growth hormones used to treat various medical conditions caused by inadequate endogenous growth hormone production. These conditions include growth hormone deficiency in children, which can lead to stunted growth, and adult growth hormone deficiency, which may cause a variety of symptoms such as decreased muscle mass, energy, and quality of life. HGH is also used in treating Turner syndrome, Prader-Willi syndrome, and chronic renal insufficiency. Beyond these therapeutic uses, HGH has applications in improving muscle mass and performance, which has led to its controversial use in sports and aging-related treatments.

The market for HGH drugs has expanded significantly due to advancements in biotechnology that have improved the efficacy and safety of these drugs. The development of recombinant DNA technology has been a pivotal factor in enabling the mass production of safe and effective HGH, which closely mimics the natural growth hormone produced in the body. This has also helped reduce the occurrence of adverse reactions compared to earlier extracts from human pituitary glands, which were used before synthetic versions became available. Furthermore, enhancements in drug delivery systems, including the development of easier-to-use injectable pens and sustained-release formulations, have improved patient compliance and treatment outcomes. As research continues to unveil new potential applications of HGH, such as in recovery from major surgeries and burns, the scope of its therapeutic benefits continues to broaden.

The growth in the human growth hormone drugs market is driven by several factors, including an increase in the prevalence of conditions requiring HGH therapy, advancements in diagnostic techniques, and a better understanding of the role of HGH in various bodily functions. Improved diagnostic methods have led to more frequent identification of growth hormone deficiencies in both children and adults, which, in turn, boosts the demand for HGH treatments. Additionally, ongoing research and development efforts aimed at expanding the applications of HGH and improving drug delivery methods are significant contributors to market growth. Moreover, there is an increasing consumer awareness and acceptance of the benefits of HGH therapy in managing age-related conditions and improving overall health outcomes, which further stimulates market expansion. Regulatory approvals in new regions and for new indications also play a crucial role in the sustained growth of this market, facilitating the wider availability and adoption of HGH therapies globally.

Select Competitors (Total 46 Featured) -

• Eli Lilly and Company
• EMD Serono, Inc.
• Ambrx, Inc.
• Ferring International Center SA
• Hanmi Pharmaceuticals Co., Ltd.
• Aileron Therapeutics, Inc.
• Alteogen, Inc.
• CinnaGen Co.
• Genexine, Inc.
• IPP Group Ltd.
• BIOSIDUS SA
• Corlison Pte. Limited
• Access Pharmaceuticals
• ERBAGIL srl
• Kynerion S.r.l.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.